Reply
We appreciate Dr Alter's complementary review of transplants for DBA. At the time our patient was transplanted, some of the papers had not yet appeared. Regarding the number of transplants, a patient in Ref. 4 rate of engraftment and reduced risk and severity of graftversus-host disease are reported with UCB. 1,2 Thus, transplants have been performed for at least 31 DBA cases with BM, and at least four cases with UCB including the one recently reported. 2 The absolute cure rates are 68% and 100%, respectively. The projected survival from KaplanMeier analysis is 63% and 100% (Figure 1 ). Although the number is limited, UCB may be a favorable source of hematopoietic cells for DBA and other bone marrow failure syndromes. 
Acute gouty arthritis following recombinant human granulocyte colony-stimulating factor therapy in an allogeneic blood stem cell donor
Of recent interest has been the use of recombinant human granulocyte colony-stimulating factor (rhG-CSF) mobilized peripheral blood stem cells for allogeneic transplantation. 1 While rhG-CSF therapy in normal allogeneic donors has been generally well tolerated, an increasing list of acute complications has been described. We would like to add another acute complication of rhG-CSF in an allogeneic blood stem cell donor, namely acute gouty arthritis.
A 65-year-old male with a history of coronary artery disease was identified as an HLA-genotypically identical stem cell donor for his sister who had acute myeloid leukemia. The donor had a history of asthma, coronary artery disease with two previous angioplastic procedures (in November 1996), degenerative arthritis of the right knee (status post right knee replacement) and hypercholesterolemia. He took pravachol 20 mg daily and one aspirin daily. He had no history of gout. Physical examination prior to administration of rhG-CSF revealed no joint swelling, erythema tenderness or deformities. A baseline uric acid level was 8.2 mg/dl (normal range 3.6 to 8.5). rhG-CSF was begun at a dose of 10 mg/kg per day. On the second day of treatment he noticed tenderness on the back of his heel (in an area of previous Achilles tendon surgery). He saw his private physician who prescribed cephalexin for presumed cellulitis. Over the next several days erythema and tenderness over the heel area progressed. On the morning of intended stem cell donation (following 5 days of G-CSF therapy), examination of left foot was remarkable for marked erythema, warmth and tenderness with fluctuance over the left heel, swelling of the plantar surface of the foot, and erythema and edema of the distal left foot and This stem cell donor may have been predisposed to gouty arthritis by virtue of having a high normal uric acid level and by taking aspirin. However a rapid rhG-CSF expansion (and turnover) of his myeloid pool probably led to precipitation of acute gouty arthritis and tendonitis.
As discussed in a recent review by Anderlini et al, 1 rhG-CSF therapy is generally well tolerated in normal stem cell donors with only an approximately 1-3% incidence of rhG-CSF discontinuation having been observed. There are, however, anecdotal reports of acute complications following rhG-CSF therapy of normal donors ranging from inflammatory conditions (eg acute iritis), 2 temporally related thrombotic events (cerebrovascular accident, myocardial infarction) 1 and more recently spontaneous splenic rupture.
